전체 프로그램 | 바이오모아

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off (Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose (Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleMacroGenicsPhase 2

Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose (Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose)

AML · AML

#AML#Antibody#Phase2#항체#면역항체+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

ADCBiologicstaleSun Yat-Sen Memorial Hospital o…Phase 3

Fluorizoparib (Fluorizoparib)

Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+4

임상시험 1상태 RECRUITING

ADCBiologicstaleFudan UniversityPhase 2

Fluzoparib (Fluzoparib)

Breast Neoplasm; Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 1상태 RECRUITING

CGTBiologicstaleMinicirclePhase 1

Follistatin and klotho gene therapy (Follistatin and klotho gene therapy)

Healthy Adults · Healthy Adults

#HealthyAdults#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

AntibodystaleUniversity of Southern Californ…Phase 2

Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab)

Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleNanjing IASO Biotechnology Co.,…Phase 1

CT103A (Fully human BCMA chimeric antigen receptor autologous T cell injection, Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleBenjamin TomlinsonPhase 1

Fully human anti CD19 CAR-T Cell Dose (Fully human anti CD19 CAR-T Cell Dose)

Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 2

Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab (Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

ADCBiologicstaleFudan UniversityPhase 2

G1: SHR-A1811 (G1: SHR-A1811)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleMediGenePhase 2

G207, an oncolytic virus (G207, an oncolytic virus)

Glioma; Astrocytoma · Glioma

#Glioma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

ADCBiologicstaleGenerate BiomedicinesPhase 1

GB-4362 (GB-4362)

Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma · Advanced Urothelial Cancer

#AdvancedUrothelialCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

115 / 177 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 0 / 1,453